-+ 0.00%
-+ 0.00%
-+ 0.00%

TME Pharma Raises EUR 750,000 Through Bond Issuances

PUBT·10/26/2026 10:21:07
Listen to the news
TME Pharma Raises EUR 750,000 Through Bond Issuances
  • TME Pharma secured EUR 750,000 through two new bond financings.
  • CEO Diede van den Ouden subscribed EUR 250,000 to an interest-free bond due June 30, 2028, without warrants or conversion rights.
  • Hexagon Capital Fund provided EUR 500,000 through 24-month bonds paying 10% annual interest, with monthly cash amortization.
  • Hexagon receives 2,000,000 three-year warrants exercisable at EUR 0.15; bond conversion is permitted only upon default, potentially causing significant dilution.
  • Existing debt maturities were extended from May 28, 2027, to June 30, 2028, extending financial visibility through the second quarter of 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TME Pharma NV published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.